Blood test for managing colorectal cancer screening
Official title: Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Context of Colorectal Cancer Screening
Run by Centre Hospitalier Universitaire de Besancon · NCT04767568 · Data updated 2026-11-12
This study is testing a blood test to see if it can help manage colorectal cancer screening for adults who have a positive test or have been diagnosed with cancer and need surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Locations | 3 sites (Besançon and 2 other locations) |
| Status | Recruiting |
| Started | March 30, 2021 |
| Main results expected | August 2027 |
| Study ends | August 2032 |
| Registry record updated | March 16, 2026 |
| Trial ID | NCT04767568 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with suspected colorectal cancer from a positive screening test or those already diagnosed with adenocarcinoma awaiting surgery.
✕Probably not a fit
Patients who are minors, pregnant, or unable to comply with the study protocol will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study explores the relevance of a blood test in the management of patients undergoing colorectal cancer screening. It focuses on individuals aged 18 and older who either have a positive immunological test indicating potential colorectal cancer or have already been diagnosed with adenocarcinoma and are candidates for surgery. The study aims to improve early detection and management of colorectal cancer, especially in light of delays caused by the COVID-19 pandemic. Participants will provide blood samples, tumor tissue, and stool collections to assess the effectiveness of the blood test.
Why it matters
Potential benefit: If successful, this approach could enhance early detection of colorectal cancer, leading to timely interventions and improved patient outcomes.
How similar studies have gone: While the use of blood tests for cancer detection is an emerging field, this specific approach in colorectal cancer screening is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged more than18 years * Cohort A : patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) or with gross bleeding OR Cohort B : patients who have already performed colonoscopy (on symptoms, or because of family history, or other ...), for whom the diagnosis of adenocarcinoma was identified by pathology prior to surgery, candidates for surgery on their colorectal tumor * Signed and dated informed consent * Patient affiliated to or beneficiary of French social security system. Exclusion Criteria: * Vulnerable persons according to the law (minors, adults under protection, persons deprived of liberty ...) * Not ability to comply with the study protocol, in the Investigator's judgment * pregnant woman * Patient in the period of exclusion of another study
Where it's running
-
CHU de Besançon
Besançon, France Recruiting -
Hôpital Nord-Franche-Comté
Montbéliard, France Not yet recruiting -
Centre Hospitalier Intercommunal de Haute-Saône
Vesoul, France Not yet recruiting
Study contacts
- Study coordinator: Christophe BORG, Pr
- Email: christophe.borg@efs.sante.fr
- Phone: +33381668166
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.